Jeffrey Dierks Sells 21,496 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jeffrey Dierks also recently made the following trade(s):

• On Friday, September 27th, Jeffrey Dierks sold 200 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.05, for a total value of $8,010.00.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $32.13 on Friday. Harmony Biosciences Holdings, Inc. has a 1 year low of $22.00 and a 1 year high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.09 and a current ratio of 3.24. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.67 and a beta of 0.73. The stock’s 50-day moving average is $36.44 and its two-hundred day moving average is $33.11.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same quarter in the previous year, the company posted $0.63 earnings per share. The firm’s revenue was up 16.0% compared to the same quarter last year. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.22 earnings per share for the current year.

Hedge Funds Weigh In On Harmony Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hedeker Wealth LLC boosted its stake in shares of Harmony Biosciences by 3.7% during the 3rd quarter. Hedeker Wealth LLC now owns 75,287 shares of the company’s stock worth $3,011,000 after acquiring an additional 2,662 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Harmony Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,931 shares of the company’s stock valued at $437,000 after purchasing an additional 4,259 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Harmony Biosciences by 8,867.7% during the third quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company’s stock worth $222,000 after purchasing an additional 5,498 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after purchasing an additional 360 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Harmony Biosciences by 20.8% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 54,274 shares of the company’s stock valued at $2,171,000 after purchasing an additional 9,329 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on HRMY. Cantor Fitzgerald lifted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday. Raymond James reissued an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Finally, UBS Group assumed coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They set a “buy” rating and a $56.00 price objective for the company. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.